FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2893913323> ?p ?o ?g. }

• W2893913323 endingPage "e504" @default.
• W2893913323 startingPage "e504" @default.
• W2893913323 abstract "Objective To analyze whether 1 of the 2 apheresis techniques, therapeutic plasma exchange (PE) or immunoadsorption (IA), is superior in treating neuromyelitis optica spectrum disorder (NMOSD) attacks and to identify predictive factors for complete remission (CR). Methods This retrospective cohort study was based on the registry of the German Neuromyelitis Optica Study Group, a nationwide network established in 2008. It recruited patients with neuromyelitis optica diagnosed according to the 2006 Wingerchuk criteria or with aquaporin-4 (AQP4-ab)-antibody–seropositive NMOSD treated at 6 regional hospitals and 16 tertiary referral centers until March 2013. Besides descriptive data analysis of patient and attack characteristics, generalized estimation equation (GEE) analyses were applied to compare the effectiveness of the 2 apheresis techniques. A GEE model was generated to assess predictors of outcome. Results Two hundred and seven attacks in 105 patients (87% AQP4-ab-antibody seropositive) were treated with at least 1 apheresis therapy. Neither PE nor IA was proven superior in the therapy of NMOSD attacks. CR was only achieved with early apheresis therapy. Strong predictors for CR were the use of apheresis therapy as first-line therapy (OR 12.27, 95% CI: 1.04–144.91, p = 0.047), time from onset of attack to start of therapy in days (OR 0.94, 95% CI: 0.89–0.99, p = 0.014), the presence of AQP4-ab-antibodies (OR 33.34, 95% CI: 1.76–631.17, p = 0.019), and monofocal attack manifestation (OR 4.71, 95% CI: 1.03–21.62, p = 0.046). Conclusions Our findings suggest early use of an apheresis therapy in NMOSD attacks, particularly in AQP4-ab-seropositive patients. No superiority was shown for one of the 2 apheresis techniques. Classification of evidence This study provides Class IV evidence that for patients with NMOSD, neither PE nor IA is superior in the treatment of attacks." @default.
• W2893913323 created "2018-10-05" @default.
• W2893913323 creator A5003159414 @default.
• W2893913323 creator A5003520588 @default.
• W2893913323 creator A5005920666 @default.
• W2893913323 creator A5008016806 @default.
• W2893913323 creator A5008942652 @default.
• W2893913323 creator A5011686938 @default.
• W2893913323 creator A5014510701 @default.
• W2893913323 creator A5018300417 @default.
• W2893913323 creator A5021067270 @default.
• W2893913323 creator A5023893355 @default.
• W2893913323 creator A5024839475 @default.
• W2893913323 creator A5029030705 @default.
• W2893913323 creator A5030982118 @default.
• W2893913323 creator A5032382577 @default.
• W2893913323 creator A5036296381 @default.
• W2893913323 creator A5037084636 @default.
• W2893913323 creator A5043996334 @default.
• W2893913323 creator A5044730858 @default.
• W2893913323 creator A5046354840 @default.
• W2893913323 creator A5050382898 @default.
• W2893913323 creator A5052848358 @default.
• W2893913323 creator A5052874564 @default.
• W2893913323 creator A5055558719 @default.
• W2893913323 creator A5056088339 @default.
• W2893913323 creator A5057183308 @default.
• W2893913323 creator A5059589220 @default.
• W2893913323 creator A5061733690 @default.
• W2893913323 creator A5063615479 @default.
• W2893913323 creator A5064280060 @default.
• W2893913323 creator A5070374515 @default.
• W2893913323 creator A5071258405 @default.
• W2893913323 creator A5071526929 @default.
• W2893913323 creator A5071852158 @default.
• W2893913323 creator A5076348059 @default.
• W2893913323 creator A5077359290 @default.
• W2893913323 creator A5081462122 @default.
• W2893913323 creator A5088512021 @default.
• W2893913323 creator A5088624556 @default.
• W2893913323 creator A5089086027 @default.
• W2893913323 date "2018-09-26" @default.
• W2893913323 modified "2023-10-18" @default.
• W2893913323 title "Apheresis therapies for NMOSD attacks" @default.
• W2893913323 cites W2002156490 @default.
• W2893913323 cites W2010507354 @default.
• W2893913323 cites W2014806902 @default.
• W2893913323 cites W2021320152 @default.
• W2893913323 cites W2021554101 @default.
• W2893913323 cites W2028844455 @default.
• W2893913323 cites W2038941725 @default.
• W2893913323 cites W2040728132 @default.
• W2893913323 cites W2058305895 @default.
• W2893913323 cites W2073144653 @default.
• W2893913323 cites W2079652702 @default.
• W2893913323 cites W2102215467 @default.
• W2893913323 cites W2104230831 @default.
• W2893913323 cites W2107941546 @default.
• W2893913323 cites W2114414511 @default.
• W2893913323 cites W2126386225 @default.
• W2893913323 cites W2132349691 @default.
• W2893913323 cites W2136132690 @default.
• W2893913323 cites W2141306695 @default.
• W2893913323 cites W2145815056 @default.
• W2893913323 cites W2155049452 @default.
• W2893913323 cites W2170189533 @default.
• W2893913323 cites W2177846153 @default.
• W2893913323 cites W2248796441 @default.
• W2893913323 cites W2764089668 @default.
• W2893913323 doi "https://doi.org/10.1212/nxi.0000000000000504" @default.
• W2893913323 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6192689" @default.
• W2893913323 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30345331" @default.
• W2893913323 hasPublicationYear "2018" @default.
• W2893913323 type Work @default.
• W2893913323 sameAs 2893913323 @default.
• W2893913323 citedByCount "161" @default.
• W2893913323 countsByYear W28939133232018 @default.
• W2893913323 countsByYear W28939133232019 @default.
• W2893913323 countsByYear W28939133232020 @default.
• W2893913323 countsByYear W28939133232021 @default.
• W2893913323 countsByYear W28939133232022 @default.
• W2893913323 countsByYear W28939133232023 @default.
• W2893913323 crossrefType "journal-article" @default.
• W2893913323 hasAuthorship W2893913323A5003159414 @default.
• W2893913323 hasAuthorship W2893913323A5003520588 @default.
• W2893913323 hasAuthorship W2893913323A5005920666 @default.
• W2893913323 hasAuthorship W2893913323A5008016806 @default.
• W2893913323 hasAuthorship W2893913323A5008942652 @default.
• W2893913323 hasAuthorship W2893913323A5011686938 @default.
• W2893913323 hasAuthorship W2893913323A5014510701 @default.
• W2893913323 hasAuthorship W2893913323A5018300417 @default.
• W2893913323 hasAuthorship W2893913323A5021067270 @default.
• W2893913323 hasAuthorship W2893913323A5023893355 @default.
• W2893913323 hasAuthorship W2893913323A5024839475 @default.
• W2893913323 hasAuthorship W2893913323A5029030705 @default.
• W2893913323 hasAuthorship W2893913323A5030982118 @default.
• W2893913323 hasAuthorship W2893913323A5032382577 @default.
• W2893913323 hasAuthorship W2893913323A5036296381 @default.

• next